Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Cheryl Nagowski
Pharmaceutical companies can struggle to understand the business opportunities presented by the federal segment, in part due to perceptions of low profit margins and overwhelming regulatory hurdles that are required to do business in this market. As companies begin to reframe the value of the federal market, it is important to establish context from a global revenue perspective.